Does the disparity in baseline characteristics of patients undergoing transcatheter aortic valve replacement with 23 mm vs. 26 mm valves impact clinical outcome?.
Citation: Catheterization & Cardiovascular Interventions. 87(1):176-82, 2016 Jan 01PMID: 26257081Institution: MedStar Heart & Vascular InstituteForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Aortic Valve Stenosis/su [Surgery] | *Aortic Valve/su [Surgery] | *Transcatheter Aortic Valve Replacement/mt [Methods] | Aged, 80 and over | Aortic Valve Stenosis/di [Diagnosis] | Aortic Valve/dg [Diagnostic Imaging] | Female | Follow-Up Studies | Humans | Male | Prosthesis Design | Retrospective Studies | Severity of Illness Index | Tomography, X-Ray Computed | Treatment OutcomeYear: 2016Local holdings: Available online from MWHC library: 1996 - present, Available in print through MWHC library: 1996 - 2006ISSN:- 1522-1946
| Item type | Current library | Collection | Call number | Status | Date due | Barcode |
|---|---|---|---|---|---|---|
| Journal Article | MedStar Authors Catalog | Article | 26257081 | Available | 26257081 |
Available online from MWHC library: 1996 - present, Available in print through MWHC library: 1996 - 2006
BACKGROUND: Transcatheter aortic valve replacement (TAVR) is currently an approved therapy for patients with severe aortic stenosis who are considered inoperable or are at high risk.
CONCLUSION: Patients undergoing TAVR with 23 and 26 mm valves have similar clinical outcomes despite significant differences in baseline characteristics. © 2015 Wiley Periodicals, Inc.
Copyright © 2015 Wiley Periodicals, Inc.
METHODS: We retrospectively examined baseline characteristics and outcomes of patients receiving a 23 mm (n=132) vs. 26 mm valve (n=81) via the transfemoral approach.
OBJECTIVES: We sought to identify if baseline characteristic differences in patients who receive a 23 mm vs. 26 mm valve impact clinical outcomes.
RESULTS: Gender (P<0.01), previous coronary artery bypass surgery (P<0.01), history of atrial fibrillation (P=0.04), and mean Society of Thoracic Surgeons (STS) score (P<0.01) were significantly different between groups. There were no significant differences in the rates of minor/major vascular complications (2.2 vs. 3.7%, P=0.68 and 13.0 vs. 12.3%, P=0.89, respectively). Bleeding complications were also comparable (major bleed 2.3 vs. 1%, P >0.99, minor bleed 19.0 vs. 22.0%, P=0.67 and life threatening bleed 7.0 vs. 5.0%, P=0.77). In-hospital death (6.0 vs. 5.0%, P >0.99), 30-day all-cause death (7.6 vs. 6.2%, P=0.69), and all-cause death at 1 year (17.4 vs. 25.9%, P=0.13) were also similar between groups. Gender, valve size, previous coronary bypass surgery and atrial fibrillation were not independently associated with mortality; however, on multivariate analysis STS score was (HR 1.11; 95% CI 1.02-1.19; P=0.01).
English